Cite
Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab.
MLA
Posselt, A. M., et al. “Islet Transplantation in Type 1 Diabetics Using an Immunosuppressive Protocol Based on the Anti-LFA-1 Antibody Efalizumab.” American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, vol. 10, no. 8, Aug. 2010, pp. 1870–80. EBSCOhost, https://doi.org/10.1111/j.1600-6143.2010.03073.x.
APA
Posselt, A. M., Bellin, M. D., Tavakol, M., Szot, G. L., Frassetto, L. A., Masharani, U., Kerlan, R. K., Fong, L., Vincenti, F. G., Hering, B. J., Bluestone, J. A., & Stock, P. G. (2010). Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 10(8), 1870–1880. https://doi.org/10.1111/j.1600-6143.2010.03073.x
Chicago
Posselt, A M, M D Bellin, M Tavakol, G L Szot, L A Frassetto, U Masharani, R K Kerlan, et al. 2010. “Islet Transplantation in Type 1 Diabetics Using an Immunosuppressive Protocol Based on the Anti-LFA-1 Antibody Efalizumab.” American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 10 (8): 1870–80. doi:10.1111/j.1600-6143.2010.03073.x.